» Articles » PMID: 37112852

Tracking the Genomic Evolution of SARS-CoV-2 for 29 Months in South Korea

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2023 Apr 28
PMID 37112852
Authors
Affiliations
Soon will be listed here.
Abstract

The pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has continued, with the persistent emergence of variants of concern (VOCs). Therefore, this study aimed to track the genomic evolution of SARS-CoV-2 strains by sequencing the spike protein for 29 months, which accounted for the majority of the COVID-19 pandemic period. A total of 109 swabs from patients with confirmed coronavirus disease 2019 (COVID-19) infection were randomly collected between March 2020 and July 2022. After genomic sequencing, we analyzed the naming systems and phylogenetic trees. Five surge peaks of COVID-19 cases have been reported in South Korea, resulting in 14,000,000 cumulative confirmed cases and 17,000 deaths. Among the sequenced samples, 34 wild-type strains and 75 VOCs, including 4 Alpha, 33 Delta, 2 Epsilon, and 36 Omicron VOCs, were identified. Omicron strains were comprised of 8 BA.1.1 (21 K), 27 BA.2 (21 L), and 1 BA.2.12.1 (22C). Phylogenetic analysis of the identified isolates and representative sequences of SARS-CoV-2 strains revealed clusters that presented the WHO VOCs. Specific or unique mutations for each VOC waxed and waned according to the variant waves. Our findings allowed recognition of the overall trends of SARS-CoV-2 isolates, which implicated replication advantage, immune evasion, and disease management.

Citing Articles

Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants.

Vishwanath S, Carnell G, Billmeier M, Ohlendorf L, Neckermann P, Asbach B NPJ Vaccines. 2024; 9(1):164.

PMID: 39251608 PMC: 11384739. DOI: 10.1038/s41541-024-00950-9.


Evaluation of Long-Term Adaptive Immune Responses Specific to SARS-CoV-2: Effect of Various Vaccination and Omicron Exposure.

Kang H, Jung J, Ko G, Lee J, Oh E Vaccines (Basel). 2024; 12(3).

PMID: 38543935 PMC: 10974805. DOI: 10.3390/vaccines12030301.


Humoral Response Kinetics and Cross-Immunity in Hospitalized Patients with SARS-CoV-2 WT, Delta, or Omicron Infections: A Comparison between Vaccinated and Unvaccinated Cohorts.

Kang H, Lee J, Jung J, Oh E Vaccines (Basel). 2023; 11(12).

PMID: 38140207 PMC: 10747008. DOI: 10.3390/vaccines11121803.


Clinical performance of SARS-CoV-2 antigen-detection rapid diagnostic test using SERS-based lateral flow immunoassay.

Yoon S, Lim Y, Kweon O, Kim T, Lee M Heliyon. 2023; 9(9):e19492.

PMID: 37809408 PMC: 10558587. DOI: 10.1016/j.heliyon.2023.e19492.

References
1.
Worobey M, Pekar J, Larsen B, Nelson M, Hill V, Joy J . The emergence of SARS-CoV-2 in Europe and North America. Science. 2020; 370(6516):564-570. PMC: 7810038. DOI: 10.1126/science.abc8169. View

2.
Fisman D, Tuite A . Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada. CMAJ. 2021; 193(42):E1619-E1625. PMC: 8562985. DOI: 10.1503/cmaj.211248. View

3.
Quadir N, Singh J, Alam A, Malik A, Rahman S, Hira S . Evolution of SARS-CoV-2: BA.4/BA.5 Variants Continues to Pose New Challenges. Viruses. 2022; 14(12). PMC: 9781647. DOI: 10.3390/v14122610. View

4.
Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L . BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022; 608(7923):593-602. PMC: 9385493. DOI: 10.1038/s41586-022-04980-y. View

5.
Rossler A, Riepler L, Bante D, von Laer D, Kimpel J . SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons. N Engl J Med. 2022; 386(7):698-700. PMC: 8781314. DOI: 10.1056/NEJMc2119236. View